NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $11.61 +0.19 (+1.65%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Intellia Therapeutics Stock (NASDAQ:NTLA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$11.53▼$11.7450-Day Range$9.20▼$14.2452-Week Range$5.90▼$23.76Volume355,152 shsAverage Volume4.07 million shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$29.05Consensus RatingModerate Buy Company Overview Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreNTLA MarketRank™: Intellia Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 112th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIntellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 12 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.07) to ($5.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.56% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 2.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted28.56% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 2.91%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.36 News SentimentIntellia Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Intellia Therapeutics this week, compared to 13 articles on an average week.Search InterestOnly 25 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have bought 551.99% more of their company's stock than they have sold. Specifically, they have bought $1,003,000.00 in company stock and sold $153,837.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesWilliam Chase Buys 100,000 Shares of Intellia Therapeutics (NASDAQ:NTLA) StockAugust 23, 2025 | insidertrades.comCathie Wood’s ARK Investment buys 191.7K shares of Intellia Therapeutics todayAugust 26 at 12:00 AM | msn.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …August 28 at 2:00 AM | Weiss Ratings (Ad)Cathie Wood’s ARK Investment buys 359K shares of Intellia Therapeutics todayAugust 25 at 11:50 PM | msn.comCathie Wood’s ARK Investment buys 150.6K shares of Intellia Therapeutics todayAugust 21, 2025 | msn.comCathie Wood’s ARK Investment buys 560.6K shares of Intellia Therapeutics todayAugust 19, 2025 | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 18, 2025 | americanbankingnews.comIntellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)August 15, 2025 | seekingalpha.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $11.66 at the beginning of 2025. Since then, NTLA shares have decreased by 2.1% and is now trading at $11.42. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.04. The company's revenue for the quarter was up 104.3% on a year-over-year basis. Read the conference call transcript. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' top institutional investors include ARK Investment Management LLC (12.57%), Sumitomo Mitsui Trust Group Inc. (2.58%), Nikko Asset Management Americas Inc. (2.49%) and Geode Capital Management LLC (2.52%). Insiders that own company stock include John M Leonard, William J Chase, Eliana Clark, James Basta, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW). Company Calendar Last Earnings8/07/2025Today8/27/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees600Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$29.05 High Price Target$64.00 Low Price Target$7.00 Potential Upside/Downside+154.4%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$519.02 million Net Margins-908.48% Pretax Margin-908.48% Return on Equity-57.48% Return on Assets-45.04% Debt Debt-to-Equity RatioN/A Current Ratio5.19 Quick Ratio5.19 Sales & Book Value Annual Sales$57.88 million Price / Sales21.18 Cash FlowN/A Price / Cash FlowN/A Book Value$6.66 per share Price / Book1.71Miscellaneous Outstanding Shares107,350,000Free Float104,019,000Market Cap$1.23 billion OptionableOptionable Beta2.31 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NTLA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.